A 52 year-old man was hospitalised for acute renal failure with thrombocytopenia and hemolytic anemia without oliguria. A haemolytic-uremic syndrome was diagnosed and prostacyclin infusion was started. Twenty-four hours later, the renal function improved as well as thrombocytopenia and anemia. Recovery occurred after 11 days of treatment. Haemolytic-uremic syndrome treatment is not well codified: plasmaphoresis, fresh frozen plasma, transfusions showed inconstant efficiency and data about prostacycline treatment are rare and often contradictory. Multicentric studies must be started in order to determine the precise benefit of this treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0248-8663(96)88400-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A potential bimodal interplay between heme and complement factor H 402H in the deregulation of the complement alternative pathway by SARS-CoV-2.
Infect Genet Evol
December 2024
2(nd) Propedeutic Department of Internal Medicine, Hippocration General Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece.
The recent discovery that the trimeric SARS-CoV-2 spike S glycoprotein carries heme within an NTD domain pocket of the S1 subunits, suggested that this virus may be cleverly utilizing heme, in addition to the S1 RBD domains, for invading target cells carrying a specific entry receptor like ACE2, TMEM106B and others. Studies during the COVID-19 pandemic revealed that the infectivity of this virus depends on cell surface heparan sulfate and that the infection induces non-canonical activation of the Complement Alternative pathway (AP) on the surface of infected cells. In our recent COVID-19 genomic studies, among the coding SNPs of interest we also detected the presence of the CFH rs1061170, rs800292 and rs1065489 within all the infected patient subgroups examined.
View Article and Find Full Text PDFCross-sectoral genomic surveillance reveals a lack of insight in sources of human infections with Shiga toxin-producing , the Netherlands, 2017 to 2023.
Euro Surveill
December 2024
Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Shiga toxin-producing (STEC) is a zoonotic pathogen associated with illness ranging from mild diarrhoea to haemolytic uremic syndrome (HUS) or even death. Cross-sectoral data sharing provides an opportunity to gain insight in reservoirs and sources of human infections and starting points for pro-active measures. Nevertheless, phylogenetic clustering of STEC strains from animals, food and human cases is low in the Dutch surveillance system.
View Article and Find Full Text PDFArticle Synopsis
- * It consists of various proteins that activate through three pathways (classical, lectin, and alternative), all converging on the C3 component to eliminate pathogens.
- * Tight regulation of complement activation is crucial, especially for the alternative pathway, as imbalances can lead to various acute and chronic diseases.
Article Synopsis
- * Unlike other conditions, hypertension typically does not have remissions and requires lifelong treatment, but its exact causes remain largely unknown despite extensive research.
- * Recent studies suggest that the complement system plays a significant role in hypertension, especially in cases of malignant hypertension linked to complement dysregulation, indicating its importance in understanding this disease.
Haemolytic uremic syndrome as a cause of chronic kidney disease stage 5 in children is in retreat: results from the Polish Registry of Kidney Replacement Therapy in children (2000-2023).
Pediatr Nephrol
November 2024
Department of Pediatrics, Nephrology and Hypertension, Medical University of Gdansk, Debinki 7, 80-211, Gdansk, Poland.
Background: Haemolytic uremic syndrome (HUS) is a life-threatening disease with a historically poor prognosis in children receiving maintenance kidney replacement therapy (KRT). This study aimed to analyse the incidence and outcome of chronic kidney disease stage 5 (CKD5) due to Escherichia coli-HUS (STEC-HUS) and complement-mediated HUS (CM-HUS) in children, compared with controls with non-HUS CKD5 over the last 24 years.
Methods: The study included 1488 children undergoing KRT in Poland between 2000 and 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!